Preclinical Development Services

In vitro and in vivo methods to provide a study setup that thoroughly determines safety and efficacy

With the most promising lead compounds selected and optimized, preclinical research provides a final characterization and safety assessment of a potential candidate prior to dosing in humans. To prepare for a First-in-Human trial (FiH), a comprehensive dossier of preclinical findings needs to be filed and approved by the regulatory authorities to allow for clinical use as an investigational new drug (IND). 

The IND-dossier requires an in-depth profiling and extrapolation of pharmacological parameters to substantiate the proposed clinical dosing-regimen to meet the requirements for the desired exposure in a human subject while minimizing its toxic effects.  

It is part of InnoSer’s ambition to serve its customers in all stages of their preclinical research. As such, we are currently in the process of applying for a GLP-accreditation.

preclinical oncology study team looking at results from in vivo oncology model

Our Approach

Readily available to guide you through the study design process and support you in accelerating your preclinical research

Scientists working in the preclinical in vitro laboratory in Belgium
The InnoSer team applies a tailored approach towards the pharmacology and toxicology aspects of your research and adjust the study design on a case-by-case basis. 

With our wide portfolio of methods and models, we can determine the transferability and reliability of your results supporting you in the transition of your compounds from bench to the clinic. Our team and network of experts are committed to accelerating the drug development process to help you deliver your treatment to patients at a fast pace. 

InnoSer can support you in developing your clinical hypothesis by using a pharmacometrics approach. Using tools such as population-based pharmacokinetic modelling (PopPK) we can support you in optimizing your clinical setup for specific substrata of patients.

new jobs at InnoSer

Contact a development expert and let’s bring your research closer to clinical trials

Our Capabilities

InnoSer is equipped to provide preclinical studies in rodents as well as safety pharmacology studies in various in vitro model systems. We have an established third-party partner to support your non-rodent preclinical studies.

InnoSer is currently expanding its offerings of in vitro models for specialty toxicology, including new approach methods (NAMs), such as genetic toxicity, mutagenicity, carcinogenicity, liver toxicity, cardiotoxicity and neurotoxicity.

In vivo pharmacology 

  • DMPK properties 
  • Therapeutic efficacy studies 
  • Pharmacokinetics 
  • MTD (Maximum Tolerated Dose) determination 
  • Dose Response Relations 
  • Translational disease models 


  • Single Dose Toxicity 
  • Repeated Dose Toxicity 
  • Toxicokinetics 
  • Medical device biocompatibility 
InnoSer logo white

Navigate The Drug Development Pipeline

Do you want to streamline your research?

Questions about how our services can accelerate your research? Reach out to one of our experts today and we can provide you with tailored advice on getting started